Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

The Future of Longevity: AI and Nanorobots to Radically Extend Life

by Team Lumida
June 25, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
person holding black and white microscope

Photo by Jaron Nix on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. AI-driven drug discovery could drastically cut down clinical trial times.
  2. Medical nanorobots may revolutionize immune systems by the 2030s.
  3. By 2040s, mind-backup systems might allow near-immortality.

What Happened?

Futurist Ray Kurzweil claims that AI will revolutionize drug discovery and medical interventions by the end of the 2020s. He believes biological simulators will soon generate crucial safety and efficacy data in hours, not years.

This shift could lead to faster drug approvals and save countless lives. Kurzweil also predicts that medical nanorobots will emerge in the 2030s, vastly enhancing our immune systems and treating metabolic diseases. By 2040s, he envisions mind-backup systems that could essentially render death obsolete.

Why It Matters?

These advancements could disrupt traditional medical models and extend human lifespans dramatically. Faster drug approvals would mean quicker access to lifesaving treatments. Medical nanorobots could address diseases that our natural immune systems can’t, such as cancer and neurodegenerative disorders.

The potential to back up our minds might lead to radical life extension, fundamentally changing the concept of mortality. Investors should note the profound implications for the healthcare and biotech sectors, which could experience exponential growth.

What’s Next?

Expect increased investment in AI-driven pharmaceutical research and biotech firms focused on nanotechnology. Regulatory landscapes will evolve to accommodate simulated trials, despite potential bureaucratic resistance. By the mid-2040s, mind-backup technologies will likely face ethical and security challenges, but Kurzweil is optimistic about overcoming these hurdles.

As these technologies become mainstream, they will likely follow the trajectory of the cell phone—starting expensive and exclusive, but eventually becoming widely accessible.

Source: Fortune Well
Tags: AI-driven drug discoverymedical nanorobotsmind-backup systemsRay Kurzweil
Previous Post

Bitcoin Crashes to $62K: What’s Behind the $150M Liquidation?

Next Post

TikTok Ban Could Dent Oracle’s Earnings: What Investors Need to Know

Recommended For You

Yoga Is the Longevity Habit Most People Underestimate

by Team Lumida
7 hours ago
woman in black tank top and black pants bending her body on floor

Key takeaways Powered by lumidawealth.com Improves flexibility, balance, and joint health, reducing injury risk with age. Lowers stress and cortisol, supporting heart and metabolic health. Enhances nervous system regulation,...

Read more

Apple Is Quietly Winning the AI Boom Without Winning AI

by Team Lumida
7 hours ago
Why Apple’s AI Approach May Save Its Reputation

Key takeaways Powered by lumidawealth.com Apple is on track to generate more than $1 billion in AI-related revenue this year, largely from App Store fees on apps like ChatGPT....

Read more

Grip Strength Is a Longevity Biomarker

by Team Lumida
1 day ago
a person lifting a barbell in a gym

Key takeaways Powered by lumidawealth.com Lower grip strength is linked to higher mortality risk. It correlates with cardiovascular health, muscle mass, and frailty. Declining grip strength often signals system-wide...

Read more

China’s AI Stocks Surge as ‘Agentic AI’ Narrative Gains Momentum

by Team Lumida
1 day ago
China’s Bold Economic Moves: What You Need to Know Now

Key takeaways Powered by lumidawealth.com Chinese AI stocks rallied sharply after bullish comments on OpenClaw’s potential. OpenClaw represents a shift from chatbots to autonomous AI agents that can perform...

Read more

Nvidia’s China Reboot Reopens a Critical AI Revenue Channel

by Team Lumida
1 day ago
Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Key takeaways Powered by lumidawealth.com Nvidia has restarted production of H200 AI chips for China, marking a potential rebound in its access to the country’s AI market. Demand signals...

Read more

Most “Longevity Drugs” Don’t Work the Way You Think

by Team Lumida
2 days ago
diagram

Key takeaways Powered by lumidawealth.com Most longevity drugs improve markers, not actual lifespan. Human evidence is weak for many popular compounds. Drug benefits are context-dependent — not universal. Lifestyle...

Read more

OpenAI Is Pulling Back on Side Projects to Win the Enterprise and Coding Race

by Team Lumida
2 days ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

Key takeaways Powered by lumidawealth.com OpenAI is shifting resources toward coding and business users, moving away from a “do everything” product strategy. Anthropic’s momentum in enterprise AI and coding...

Read more

Walking After Meals Is a Simple Hack for Blood Sugar Control

by Team Lumida
3 days ago
woman walking on pathway during daytime

Key takeaways Powered by lumidawealth.com Just 10–15 minutes of walking after meals can lower post-meal blood sugar spikes. Light activity helps muscles absorb glucose without needing as much insulin....

Read more

Ozempic’s Patent Expiry Could Make India the Biggest Test Case for Cheap Weight-Loss Drugs

by Team Lumida
3 days ago
Ozempic’s Patent Expiry Could Make India the Biggest Test Case for Cheap Weight-Loss Drugs

Key takeaways Powered by lumidawealth.com India is about to become a major generic GLP-1 market, with multiple drugmakers preparing cheaper semaglutide launches after patent expiry. Prices could fall by...

Read more

AI Is Repricing San Francisco Real Estate Faster Than the Rest of America

by Team Lumida
3 days ago
AI Investment Boom: How Tech Giants Are Leading the Charge

Key takeaways Powered by lumidawealth.com San Francisco housing is rebounding aggressively, driven by AI-related wealth, tighter inventory, and improving city sentiment. Single-family home prices rose 23% year over year...

Read more
Next Post
a red cube with white text

TikTok Ban Could Dent Oracle's Earnings: What Investors Need to Know

a person holding a phone

AI and Crypto Shakeup: Nvidia and Bitcoin's Massive Drops Explained

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

a bitcoin sitting on top of a pile of money

CFTC Clears Path for Spot Crypto Trading on Futures Exchanges, Expanding U.S. Market Access

December 5, 2025
a white square with a blue logo on it

Meta Poaches Three OpenAI Researchers to Bolster Superintelligence Efforts

June 26, 2025
Geopolitical Forces Shape Oil Market Dynamics

IEA Warns of Oil Surplus Amid Trade Tensions and OPEC+ Output Uncertainty

March 13, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018